Albiglutide: a review of its use in patients with type 2 diabetes mellitus

Drugs
Hannah A Blair, Gillian M Keating

Abstract

Albiglutide (Eperzan(®), Tanzeum(®)), administered subcutaneously once weekly, is a glucagon-like peptide (GLP)-1 receptor agonist approved for the treatment of type 2 diabetes mellitus in several countries. Albiglutide has a longer half-life than native GLP-1, since it is resistant to degradation by the dipeptidyl peptidase-4 enzyme. As an incretin mimetic, albiglutide enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, delays gastric emptying and reduces food intake. Several phase III clinical trials have demonstrated the efficacy of albiglutide in terms of improving glycaemic control in patients with inadequately controlled type 2 diabetes, including its use as monotherapy or add-on therapy to other antidiabetic agents (e.g. metformin, sulfonylureas, thiazolidinediones and insulins). In addition to improving glycaemic control, albiglutide had beneficial effects on bodyweight. These improvements in glycaemic control and reductions in bodyweight were maintained during long-term treatment (up to 3 years). Albiglutide was generally well tolerated in clinical trials, with mild to moderate gastrointestinal adverse events seen most commonly. Albiglutide has a convenient once-weekly administrat...Continue Reading

References

Jan 25, 2008·Diabetic Medicine : a Journal of the British Diabetic Association·S A AmielK Jameson
Sep 25, 2008·The Journal of Clinical Endocrinology and Metabolism·Jessica E MatthewsUNKNOWN Albiglutide Study Group
Jan 5, 2011·Diabetes, Obesity & Metabolism·W H PolonskyJ H Best
May 24, 2011·Current Medical Research and Opinion·Stuart A RossRobert J Ligthelm
Oct 28, 2011·The Journal of Clinical Endocrinology and Metabolism·Belinda GierMichael W Yeh
Jun 8, 2013·Bioorganic & Medicinal Chemistry Letters·Martin LorenzMichael Wagner
Aug 2, 2013·Diabetes Care·Michael A Nauck, Nele Friedrich
Dec 21, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Feb 11, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Borje DarpoRickey R Reinhardt
Feb 28, 2014·The New England Journal of Medicine·Amy G EganCurtis Rosebraugh
Apr 26, 2014·The Journal of Clinical Investigation·Stephanie SisleyRandy J Seeley
Mar 18, 2013·Journal of Diabetes Investigation·Yutaka Seino, Daisuke Yabe
Aug 20, 2014·The Annals of Pharmacotherapy·Jennifer M Trujillo, Wesley Nuffer
Sep 10, 2014·The Journal of Clinical Investigation·Anna SecherLotte Bjerre Knudsen
Nov 12, 2014·Postgraduate Medicine·Malcolm A YoungRickey R Reinhardt
Nov 21, 2014·Journal of Diabetes Investigation·Daisuke Yabe, Yutaka Seino

❮ Previous
Next ❯

Citations

Jul 15, 2015·Expert Opinion on Drug Metabolism & Toxicology·Andreas BrøndenMikkel Christensen
Dec 25, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Dorthe ViuffKenneth A Howard
Dec 15, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Caslin A GilroyAshutosh Chilkoti
Dec 3, 2016·Therapeutic Advances in Drug Safety·Nidhi JainChristopher W Sands
Feb 15, 2019·Advanced Healthcare Materials·Anastasia K Varanko, Ashutosh Chilkoti
Feb 8, 2019·Current Pharmaceutical Design·Huanbo TanPeijian Zou
May 3, 2019·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Amita Datta-Mannan
Jan 5, 2017·Clinical Pharmacokinetics·Andreas BrøndenMikkel B Christensen
Mar 26, 2021·Molecular Biology Reports·Amit GuptaAbdul Hafeez
Nov 14, 2017·Journal of the American Chemical Society·Xing ChenE James Petersson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.